Market Place
Sourcing Support
Satsuma & SNBL Receive FDA Acceptance of STS101 NDA for Migraine
26 Nov 2024 //
PR NEWSWIRE
Satsuma Resubmits NDA for STS101 (Migraine Treatment)
30 Oct 2024 //
PR NEWSWIRE
Satsuma And SNBL Announce Publication Of STS101 Study
08 Oct 2024 //
PR NEWSWIRE
FDA Issues Complete Response Letter for Satsuma’s STS101
19 Jan 2024 //
PRESS RELEASE
Satsuma Pharma and SNBL Announce Three Abstracts on STS101
15 Jun 2023 //
GLOBENEWSWIRE
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101
18 May 2023 //
GLOBENEWSWIRE
SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General Louisiana
21 Apr 2023 //
BUSINESSWIRE
Satsuma Announces 3Abstracts Accepted at The 75th American Academy Neurology
21 Apr 2023 //
GLOBENEWSWIRE
With skin in the game, Satsuma`s partner offers buyout
17 Apr 2023 //
FIERCE BIOTECH
Satsuma peels off staff, cutting head count by 36% to save cash
29 Mar 2023 //
FIERCE BIOTECH
Satsuma Reports Fourth Quarter and Full Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
Satsuma to Participate in the Virtual SVB Securities Global Biopharma Conference
02 Feb 2023 //
GLOBENEWSWIRE
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
20 Dec 2022 //
GLOBENEWSWIRE
Satsuma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
23 Nov 2022 //
GLOBENEWSWIRE
Satsuma in the red after 2nd phase 3 migraine flop spurs search for alternatives
15 Nov 2022 //
FIERCEBIOTECH
Satsuma Pharma Announces Topline Results from SUMMIT Phase 3 Trial of STS101
14 Nov 2022 //
GLOBENEWSWIRE
Satsuma Pharmaceuticals Reports 3Q FYR and Recent Business Highlights
03 Nov 2022 //
GLOBENEWSWIRE
Satsuma peels off fresh strip of long-term migraine study data
26 Sep 2022 //
FIERCEPHARMA
Satsuma Announces Positive Results from the Ongoing STS101 ASCEND Ph3
20 Sep 2022 //
GLOBENEWSWIRE
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Satsuma Pharma Reports Q2 2022 Financial Results; Progress in STS101 Program
09 Aug 2022 //
GLOBENEWSWIRE
Satsuma Pharma Completes Enrollment in PIII Efficacy Trial of STS101 in Migraine
02 Aug 2022 //
GLOBENEWSWIRE
Satsuma Pharma Announces Five Abstracts Accepted for Presentation at AHS
09 Jun 2022 //
GLOBENEWSWIRE
Satsuma Pharma Hosting Webinar on Acute Treatment of Migraine, DHE, and STS101
07 Jun 2022 //
GLOBENEWSWIRE
Satsuma Pharmaceuticals to Present at the H.C. Wainwright Conference
11 May 2022 //
GLOBENEWSWIRE
Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Satsuma Pharma Reports 2021 FY and Q4 Financial Results
15 Mar 2022 //
GLOBENEWSWIRE
Satsuma Pharma Announces Abstracts Accepted for Presentation at AAN 2022
03 Mar 2022 //
GLOBENEWSWIRE
Satsuma Pharma to Present at the Virtual 11th Annual SVB Leerink Conference
08 Feb 2022 //
GLOBENEWSWIRE
Cyrano Appoints John Kollins to its Board of Directors
09 Nov 2021 //
PRNEWSWIRE
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch BOD
12 Oct 2021 //
GLOBENEWSWIRE
Satsuma to Present at the Cantor Virtual Global Healthcare Conference
28 Sep 2021 //
GLOBENEWSWIRE
Satsuma 1st Subject Randomized in SUMMITâ„¢, a Phase 3 Efficacy Trial of STS101
28 Jul 2021 //
GLOBENEWSWIRE
Satsuma Pharmaceuticals to Present at SVB Leerink’s CNS Forum
22 Jun 2021 //
GLOBENEWSWIRE
Satsuma Pharma Announces Positive Results From Phase 1 Trial of STS101
16 Jun 2021 //
GLOBENEWSWIRE
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
01 Mar 2021 //
GLOBENEWSWIRE
Phase 3 migraine flop squashes Satsuma`s stock price
11 Sep 2020 //
FIERCE BIOTECH
Phase III migraine flop sends a small-cap biotech player into a deadly tailspin
10 Sep 2020 //
ENDPTS
Satsuma Pharma`s STS101 flunks late-stage migraine study, shares down 84%
09 Sep 2020 //
SEEKINGALPHA
Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCEND™
06 Aug 2020 //
GLOBENEWSWIRE
Satsuma to Present Two Posters at the American Headache Society
11 Jun 2020 //
GLOBENEWSWIRE
Satsuma Completes Enrollment in Pivotal Phase 3 EMERGE trial of STS101
01 Jun 2020 //
GLOBENEWSWIRE
Satsuma Pharmaceuticals Announces Poster Presentations on ASCO 2020
18 May 2020 //
GLOBENEWSWIRE
Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1
28 Jan 2020 //
GLOBENEWSWIRE
Satsuma Announces 1st Patient Dosed in EMERGE™, a Ph3 Efficacy Trial of STS101
23 Aug 2019 //
PR NEWSWIRE
Why Satsuma investors see room for another migraine therapy
25 Apr 2019 //
ENDPTS
Satsuma Pharmaceuticals Raises $62 M in Series B Preferred Stock Financing
24 Apr 2019 //
PR NEWSWIRE
Satsuma Provides Corporate Update & Prepares to Advance Lead Product STS101
21 Feb 2019 //
PR NEWSWIRE
Satsuma Pharma Provides Corporate Update & Prepares to Advance Lead Candidate
20 Feb 2019 //
PR NEWSWIRE
Satsuma Pharmaceuticals Announces Presentations at Upcoming Investor Conferences
14 Feb 2019 //
PR NEWSWIRE
